Affordable Access

Phase II, randomized, open-label, community-based trial to compare the safety and activity of combination therapy with recombinant interferon-alpha2b and zidovudine versus zidovudine alone in patients with asymptomatic to mildly symptomatic HIV infection. HIV Protocol C91-253 Study Team.

Authors
  • Krown, S E
  • Aeppli, D
  • Balfour, H H Jr
Type
Published Article
Journal
Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology
Publisher
Ovid Technologies (Wolters Kluwer) - Lippincott Williams & Wilkins
Publication Date
Mar 01, 1999
Volume
20
Issue
3
Pages
245–254
Identifiers
PMID: 10077172
Source
Medline
License
Unknown

Abstract

At the doses and schedule used in this study, the combination of ZDV with rIFN-alpha2b was not therapeutically superior to ZDV alone and was less well tolerated. The addition of rIFN-alpha2b to ZDV did not prevent or delay the development of ZDV resistance.

Report this publication

Statistics

Seen <100 times